Targeting Debilitating and Life Threatening Inflammation

Hillhurst has developed products based on a novel technology targeting a protective cellular metabolic pathway (heme oxygenase) thought to limit inflammatory processes, prevent cell death and, in sickle cell disease, block the polymerization of hemoglobin that is the primary cause of complications.

Hillhurst is developing a number of additional, early stage products based on its core technology and understanding of the protective heme oxygenase enzyme that generates carbon monoxide throughout the body.